RVU-27065 / Ryvu Therap - LARVOL DELTA

Characterization of RVU-27065 a novel small-molecule STING agonist suitable for systemic administration (SITC 2021) - "The compound is characterized by high in vitro potency which translates to efficacy in vivo in preclinical animal models. Drug-like properties, excellent selectivity and a good safety profile make RVU-27065 an attractive candidate for further development for standalone as well as targeted delivery, which holds high potential for improved immunotherapy in cancer patients."

Breast Cancer • Oncology • Solid Tumor • STING

Ryvu Therapeutics Reports Q3 2021 Financial Results (PRNewswire) - "Two Poster Presentations of HPK1 and STING programs at SITC's 36th Annual Meeting. The second poster will highlight a novel small-molecule STING agonist, RVU-27065."

Preclinical • Oncology • Solid Tumor

Ryvu Therapeutics to Highlight HPK1 and STING Programs at the Upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting (Ryvu Therapeutics Press Release) - "Ryvu Therapeutics...announced today that it will present two research posters on its HPK1 and STING programs at the upcoming Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021) taking place on November 10 – 14, 2021, in Washington, DC. Ryvu will present a poster on novel, orally administered HPK1 inhibitors which exhibit nanomolar activity in an immunosuppressive environment....The second poster will highlight a novel small-molecule STING agonist, RVU-27065."

Preclinical • Oncology • Solid Tumor